Related Experiment Video
Updated: Aug 15, 2026
05:56
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
Ziconotide: can we use it in palliative care?
1Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, California, USA.
The American Journal of Hospice & Palliative Care
|October 18, 2005
Summary
Ziconotide (PRIALT) offers a new nonopioid approach for chronic pain by blocking N-type calcium channels. Clinical trials show it effectively reduces pain in patients unresponsive to other treatments.
Area of Science:
- Pharmacology
- Neuroscience
- Pain Management
Background:
- Chronic pain affects millions, with limited non-addictive treatment options.
- Current treatments like systemic analgesics and intrathecal morphine have limitations or side effects.
- Ziconotide (PRIALT) represents a novel therapeutic agent for refractory pain conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of ziconotide as a nonopioid treatment for chronic pain.
- To investigate ziconotide's mechanism of action as a selective N-type calcium channel blocker.
- To assess ziconotide's effectiveness in patients refractory to existing pain therapies.
Main Methods:
- A clinical trial comparing ziconotide to placebo in patients with chronic pain.
- Administration of ziconotide via intrathecal infusion.
- Assessment of analgesic effects and patient-reported outcomes.
Main Results:
- Ziconotide demonstrated a significant analgesic effect compared to placebo.
- The drug's benefit was observed in patients intolerant or refractory to other pain treatments.
- Ziconotide acts by selectively blocking neuronal N-type voltage-sensitive calcium channels.
Conclusions:
- Ziconotide is the first N-type calcium channel blocker (NCCB) approved for chronic pain.
- It offers a new therapeutic option for patients with difficult-to-treat pain.
- Ziconotide provides a nonopioid alternative for managing chronic pain effectively.
Related Concept Videos
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:20Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...